Results 141 to 150 of about 1,094,944 (319)
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Clumpy ultracompact H II regions – I. Fully supersonic wind-blown models [PDF]
J. E. Dyson +2 more
openalex +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
DYNAMICS OF H II REGIONS [PDF]
openaire +1 more source
Isolated Extragalactic H II Regions
Wallace L. W. Sargent, Leonard Searle
openaire +1 more source
THE METALLICITY PROFILE OF M31 FROM SPECTROSCOPY OF HUNDREDS OF H II REGIONS AND PNe [PDF]
Nathan E. Sanders +3 more
openalex +1 more source
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source
Studies of ultracompact H II regions -- III. Near-infrared survey of selected regions [PDF]
Andrew Walsh +3 more
openalex +1 more source

